A study of DCR-PHXC for the treatment of primary hyperoxaluria (PH).

Trial Profile

A study of DCR-PHXC for the treatment of primary hyperoxaluria (PH).

Planning
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs DCR PHXC (Primary)
  • Indications Primary hyperoxaluria
  • Focus Adverse reactions; First in man; Proof of concept
  • Most Recent Events

    • 16 Oct 2017 According to a Dicerna Pharmaceuticals media release, the company has submitted a clinical trial application (CTA) to the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. The company plans to submit additional CTAs in other European countries later this year. Initial data from this trial is expected in 2018.
    • 08 May 2017 This trial is expected to begin in the first quarter of 2018, according to a Dicerna Pharmaceuticals media release.
    • 22 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top